Apremilast
Stories
-
Amgen posts results of Phase 3b long-term extension study of apremilast in pediatric psoriasis
The study, enrolling 160 participants, was terminated after a primary completion date of October 30, 2025. It evaluated up to 208 weeks of open-label apremilast therapy followed by an 8-week observational follow-up.